METHODS.
Protein levels were quantified by western blotting of heart lysates or sub-cellular fractions. Cytochrome c (cyt c) release from mitochondria was characterized by gel filtration of S100 fractions. The proportion of cardiomyocytes showing elevated pro-and anti-apoptotic signaling was analyzed by immunohistochemistry and TUNEL staining.
RESULTS.
Apoptosis in the transgenic heart begins to rise relative to controls at 3 weeks of age, peaks 1 week later, and then declines at a time when Bcl2 levels rise and remain high (Fig.  1) . Apoptosis is associated with the release of cyt c and translocation of BAX onto mitochondria (Fig. 2) . Counteracting these pro-apoptotic signals is the upregulation of a number of anti-apoptotic proteins which inhibit different steps in mitochondrial apoptotic signaling ( Fig. 2 ): Bfl1 (BAX activity {4}), Bcl2 and Bcl-xL (BAX-induced release of cyt c {5}), Hsp27 (activation of caspase 9 {6}), XIAP (activation of caspase 3 {7}). Although total levels of both Bcl2 and Bcl-xL are elevated, only Bcl2 is also upregulated in mitochondria (Fig. 2) . Immunohistochemical analysis for Bcl2 and cyt c shows that by 5 weeks of age all cardiomyocytes in the transgenic heart show upregulation of Bcl2 and release of cyt c. Proteins known to protect against apoptosis (Bcl-xL, Bcl-2, XIAP, Bfl-1, and HSP27) are upregulated at the whole heart (total) level. HSPs 60 and 72 show no change, demonstrating that changes reflect a specific response. Despite this heightened protection, we see increased release of cytochrome c (cytosol) and increased proapoptotic BAX on mitochondria. Much of the Bcl-2 increase is due to mitochondrially localized protein, while the Bcl-xL response is not targeted to mitochondria. Specificity controls in the mitochondrial fraction are cyt c and HSP 60.
SUMMARY.
Rising levels of mtDNA mutations cause chronic apoptosis in the mouse heart, possibly mediated by the release of cyt c. This pro-apoptotic signal is counteracted by a persistent upregulation of anti-apoptotic proteins that inhibit different steps in the apoptotic pathway. This altered balance may establish a compensated state that contributes to the pathogenesis of mtDNA mutations. Supported by grants from the American Heart Association, the Alzheimer Association, and the Aging and Heart, Lung & Blood Institutes of the NIH.
(Additional figures at end of paper.) Cytochrome c release was monitored as an increase in cyt c immunoreactivity in paraffin-embedded slides. Note the overall increase in cyt c immunoreactivity in the transgenic heart (TG) at 5 weeks-of-age compared to the control heart (CT). As the amount of cyt c in transgenic hearts -either in mitochondria or in whole cell extracts -is at most only slightly higher than controls, we interpret the increased immunoreactivity as an indicator of cyt c release. Importantly, at 3 weeks of age, a patchy cellular pattern of increased immunofluorescence is observed, as would be expected if the rising frequencies of mtDNA mutations need to cross a threshold to induce cyt c release. Given the stochastic mechanism causing mtDNA mutations in this model, not all cells are expected to arrive at that threshold at the same age. By 5 weeks of age, all cells appear to be involved in the disease process. Given the cytotoxicity of released cyt c, cell death remains remarkably in check due to a protective response. 
